How times a day do you take this medicine?
What is Chloramphenicol (Mycogynax)?
Chloramphenicol (Mycogynax) belongs to the family of medicines called antibiotics. Chloramphenicol (Mycogynax) ophthalmic preparations are used to treat infections of the eye. Chloramphenicol (Mycogynax) may be given alone or with other medicines that are taken by mouth for eye infections.
Chloramphenicol (Mycogynax) is available only with your doctor's prescription.
Chloramphenicol (Mycogynax) indications
In accord with the concepts in the Warning Box and this INDICATIONS AND USAGE section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, Chloramphenicol (Mycogynax) may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of Chloramphenicol (Mycogynax) rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above.
1. Acute infections caused by Salmonella typhi*
It is not recommended for the routine treatment of the typhoid carrier state.
2. Serious infections caused by susceptible strains in accordance with the concepts expressed above:
a) Salmonella species
b) H. influenzae, specially meningeal infections
d) Lymphogranuloma-psittacosis group
e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections
f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents.
3. Cystic fibrosis regimens
*In treatment of typhoid fever some authorities recommend that Chloramphenicol (Mycogynax) be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse.
How should I use Chloramphenicol (Mycogynax)?
Use Chloramphenicol (Mycogynax) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Chloramphenicol (Mycogynax) is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Chloramphenicol (Mycogynax) at home, carefully follow the injection procedures taught to you by your health care provider.
- If Chloramphenicol (Mycogynax) contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.
- To clear up your infection completely, continue using Chloramphenicol (Mycogynax) for the full course of treatment even if you feel better in a few days.
- Keep this product, as well as syringes and needles, out of the reach of children. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.
- If you miss a dose of Chloramphenicol (Mycogynax), use it as soon as possible. Then use your doses at evenly spaced times as directed by your doctor. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Chloramphenicol (Mycogynax).
Uses of Chloramphenicol (Mycogynax) in details
Chloramphenicol (Mycogynax) is used to treat severe life-threatening infections, particularly those caused by Haemophilus influenzae and typhoid fever. It is also used to treat certain eye infections. It is also used in the treatment of a wide range of bacterial infections of the outer ear.
Chloramphenicol (Mycogynax) description
Each 100 g contains Chloramphenicol (Mycogynax) 1 g.
Chloramphenicol (Mycogynax) dosage
Chloramphenicol (Mycogynax), like other potent drugs, should be prescribed at recommended doses known to have therapeutic activity. Administration of 50 mg/kg/day in divided doses will produce blood levels of the magnitude to which the majority of susceptible microorganisms will respond.
As soon as feasible an oral dosage form of another appropriate antibiotic should be substituted for intravenous Chloramphenicol (Mycogynax) sodium succinate.
The following method of administration is recommended:
Intravenously as a 10% (100 mg/mL) solution to be injected over at least a one-minute interval. This is prepared by the addition of 10 mL of an aqueous diluent such as water for injection or 5% dextrose injection.
Adults should receive 50 mg/kg/day in divided doses at 6-hour intervals. In exceptional cases patients with infections due to moderately resistant organisms may require increased dosage up to 100 mg/kg/day to achieve blood levels inhibiting the pathogen, but these high doses should be decreased as soon as possible. Adults with impairment of hepatic or renal function or both may have reduced ability to metabolize and excrete the drug. In instances of impaired metabolic processes, dosages should be adjusted accordingly. Precise control of concentration of the drug in the blood should be carefully followed in patients with impaired metabolic processes by the available microtechniques (information available on request).
Dosage of 50 mg/kg/day divided into 4 doses at 6-hour intervals yields blood levels in the range effective against most susceptible organisms. Severe infections (eg, bacteremia or meningitis), especially when adequate cerebrospinal fluid concentrations are desired, may require dosage up to 100 mg/kg/day; however, it is recommended that dosage be reduced to 50 mg/kg/day as soon as possible. Children with impaired liver or kidney function may retain excessive amounts of the drug.
A total of 25 mg/kg/day in 4 equal doses at 6-hour intervals usually produces and maintains concentrations in blood and tissues adequate to control most infections for which the drug is indicated. Increased dosage in these individuals, demanded by severe infections, should be given only to maintain the blood concentration within a therapeutically effective range. After the first two weeks of life, full-term neonates ordinarily may receive up to a total of 50 mg/kg/day equally divided into 4 doses at 6-hour intervals. These dosage recommendations are extremely important because blood concentration in all premature and full-term neonates under two weeks of age differs from that of other infants neonates. This difference is due to variations in the maturity of the metabolic functions of the liver and the kidneys.
When these functions are immature (or seriously impaired in adults), high concentrations of the drug are found which tend to increase with succeeding doses.
Pediatric Patients with Immature Metabolic Processes
In young infants and other pediatric patients in whom immature metabolic functions are suspected, a dose of 25 mg/kg/day will usually produce therapeutic concentrations of the drug in the blood. In this group particularly, the concentration of the drug in the blood should be carefully followed by microtechniques. (Information available on request.)
Chloramphenicol (Mycogynax) interactions
There are no known drug interactions arising from the use of topical medication. Vitamin E administered systemically can increase the pharmacological action of insulin and digital. The absorption and accumulation of vitamin A can be reduced respectively by Neomycin sulphate some drugs such corticosteroids administered for prolonged periods, phenobarbital, caffeine and alcohol. And ’demonstrated a significant relationship between vitamin D and phenytoin or phenobarbital.
Among patients treated with these drugs for a long time, it is noted a high incidence of rickets and osteomalacia. Chloramphenicol (Mycogynax) irreversibly inhibits the enzymes of hepatic microsomal cytochrome P450 complex and this may result in a longer half-lives of drugs metabolized by this system (dicoumarol, phenytoin, chlorpropamide and tolbutamide). Chronic administration of phenobarbital or acute administration of rifampicin shorten the half-lives of Chloramphenicol (Mycogynax) and subsequent formation of sub-therapeutic concentrations of the drug.
Chloramphenicol (Mycogynax) side effects
1. Blood Dyscrasias
The most serious adverse effect of Chloramphenicol (Mycogynax) is bone marrow depression. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of Chloramphenicol (Mycogynax). An irreversible type of marrow depression leading to aplastic anemia with a high rate of mortality is characterized by the appearance weeks or months after therapy of bone marrow aplastic or hypoplasia. Peripherally, pancytopenia is most often observed, but in a small number of cases only one or two of the three major cell types (erythrocytes, leukocytes, platelets) may be depressed.
A reversible type of bone marrow depression, which is dose related, may occur. This type of marrow depression is characterized by vacuolization of the erythroid cells, reduction of reticulocytes and leukopenia, and responds promptly to the withdrawal of Chloramphenicol (Mycogynax).
An exact determination of the risk of serious and fatal blood dyscrasias is not possible because of lack of accurate information regarding 1) the size of the population at risk, 2) the total number of drug-associated dyscrasias, and 3) the total number of non-drug associated dyscrasias.
In a report to the California State Assembly by the California Medical Association and the State Department of Public Health in January 1967, the risk of fatal aplastic anemia was estimated at 1:24,200 to 1:40,500 based on two dosage levels.
There have been reports of aplastic anemia attributed to Chloramphenicol (Mycogynax) which later terminated in leukemia.
Paroxysmal nocturnal hemoglobinuria has been reported.
2. Gastrointestinal Reactions
Nausea, vomiting, glossitis and stomatitis, diarrhea and enterocolitis may occur in low incidence.
3. Neurotoxic Reactions
Headache, mild depression, mental confusion, and delirium have been described in patients receiving Chloramphenicol (Mycogynax). Optic and peripheral neuritis have been reported, usually following long-term therapy. If this occurs, the drug should be promptly withdrawn.
4. Hypersensitivity Reactions
Fever, macular and vesicular rashes, angioedema, urticaria, and anaphylaxis may occur. Herxheimer’s reactions have occurred during therapy for typhoid fever.
5. "Gray Syndrome"
Toxic reactions including fatalities have occurred in the premature and neonate; the signs and symptoms associated with these reactions have been referred to as the “gray syndrome.” One case of gray syndrome has been reported in a neonate born to a mother having received Chloramphenicol (Mycogynax) during labor. One case has been reported in a 3-month-old infant. The following summarizes the clinical and laboratory studies that have been made on these patients:
a) In most cases therapy with Chloramphenicol (Mycogynax) had been instituted within the first 48 hours of life.
b) Symptoms first appeared after 3 to 4 days of continued treatment with high doses of Chloramphenicol (Mycogynax).
c) The symptoms appeared in the following order:
(1) abdominal distension with or without emesis;
(2) progressive pallid cyanosis;
(3) vasomotor collapse, frequently accompanied by irregular respiration;
(4) death within a few hours of onset of these symptoms.
d) The progression of symptoms from onset to exitus was accelerated with higher dose schedules.
e)Preliminary blood serum level studies revealed unusually high concentrations of Chloramphenicol (Mycogynax) (over 90 mcg/mL after repeated doses).
f) Termination of therapy upon early evidence of the associated symptomatology frequently reversed the process with complete recovery.
Chloramphenicol (Mycogynax) contraindications
Chloramphenicol (Mycogynax) Lotion is contraindicated for premature neonates because their skin may be more permeable than full term infants and their liver enzymes may not be sufficiently developed. It is also contraindicated for patients with Norwegian (crusted) scabies due to possible increased absorption. It is also contraindicated for patients with known seizure disorders and for individuals with a known sensitivity to the product or any of its components.
What is Dexamethasone (Mycogynax)?
Dexamethasone (Mycogynax) intravitreal implant is used to treat an eye disease called macular edema (swelling of the back of the eye). Macular edema occurs when a blood vessel in the eye is clogged. This causes vision changes that must be treated right away. Dexamethasone (Mycogynax) is a corticosteroid (steroid medicine) that helps reduce the swelling in the eye.
Dexamethasone (Mycogynax) intravitreal implant is also used to treat an eye disease called uveitis (swelling in the middle part of the eye). Dexamethasone (Mycogynax) is also used to treat diabetic macular edema in patients with artificial lens implant or are scheduled for cataract surgery.
Dexamethasone (Mycogynax) is to be given only by or under the supervision of your doctor.
Dexamethasone (Mycogynax) indications
Inflammatory joint diseases
Adult: 0.8-4 mg depending on the size of the affected joint. For soft-tissue inj, 2-6 mg may be used. May repeat inj every 3-5 days to every 2-3 wk.
Prophylaxis of nausea and vomiting associated with cytotoxic therapy
Adult: Prevention: 10-20 mg 15-30 minutes before admin of chemotherapy on each treatment day. For continuous infusion regimen: 10 mg every 12 hr on each treatment day. For midly emetogenic regimen: 4 mg every 4-6 hr.
Adult: As phosphate: Initially, 40 mg or 1-6 mg/kg as a single IV inj, may repeat every 2-6 hr. Continue high-dose treatment only until patient's condition has stabilised and not to be continued beyond 48-72 hr.
Adult: 0.15 mg/kg 4 times daily, to be given 10-20 min before or with the 1st dose of anti-infective treatment. Treatment should be given for the first 2-4 days of the anti-infective treatment.
Child: As phosphate: 2 mth-18 yr: 150 mcg/kg every 6 hr for 4 days, starting before or with 1st dose of antibacterial treatment.
Adult: As 0.1% suspension: Apply 1-2 drops into the affected eye/s 4-6 times daily in mild disease, up to hrly admin in more severe disease. As 0.05% ointment: Apply 0.5-1 inch ribbon of ointment into the conjunctival sac(s) up to 4 times daily. Reduce to once daily dosing once conditon has improved.
Adult: 0.75-9 mg daily in 2-4 divided doses; may also be given via IM/IV admin.
Child: 1 mth-18 yr: 10-100 mcg/kg daily in 1-2 divided doses via oral admin, adjusted according to response; up to 300 micrograms/kg daily may be used in emergency situations.
Screening test for Cushing's syndrome
Adult: 0.5 mg every 6 hr for 48 hr after determining baseline 24-hr urinary 17-hydroxycorticosteroid (17-OHCS) concentrations. During the second 24 hr of Dexamethasone (Mycogynax) admin, urine is collected and analysed for 17-OHCS. Alternatively, after a baseline plasma cortisol determination, 1 mg may be given at 11 pm and plasma cortisol determined at 8 am the next morning. Plasma cortisol and urinary output of 17-OHCS are depressed after Dexamethasone (Mycogynax) admin in normal individuals but remain at basal levels in patients with Cushing's syndrome.
Acute exacerbations in multiple sclerosis
Adult: 30 mg daily for 1 wk followed by 4-12 mg daily for 1 mth.
Child: 1 mth-12 yr: 100-400 mcg/kg daily in 1-2 divided doses; 12-18 yr: Initially 0.5-24 mg daily. Max. 24 mg daily.
Cerebral oedema caused by malignancy
Adult: As phosphate: 10 mg IV followed by 4 mg IM every 6 hr until response is achieved, usually after 12-24 hr. May reduce dosage after 2-4 days then gradually discontinued over 5-7 days. In severe cases, an initial dose of 50 mg IV may be given on day 1, with 8 mg every 2 hr, reduced gradually over 7-13 days. Maintenance dose: 2 mg 2-3 times daily.
Child: As phosphate: <35 kg: Initially 20 mg, then 4 mg every 3 hr for 3 days, then 4 mg every 6 hr for 1 day, then 2 mg every 6 hr for 4 days, then decrease by 1 mg daily. >35 kg: Initially 25 mg, then 4 mg every 2 hr for 3 days, then 4 mg every 4 hr for 1 day, then 4 mg every 6 hr for 4 days, then decrease by 2 mg daily. Doses are given via IV inj.
How should I use Dexamethasone (Mycogynax)?
Use Dexamethasone (Mycogynax) suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- If your doctor prescribed more than 1 eye medicine, find out the best order for using each medicine.
- Remove contact lenses before using Dexamethasone (Mycogynax) suspension.
- Shake well before each use.
- To use Dexamethasone (Mycogynax) suspension in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
- If you miss a dose of Dexamethasone (Mycogynax) suspension, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Dexamethasone (Mycogynax) suspension.
Uses of Dexamethasone (Mycogynax) in details
This medication is used to treat various conditions such as severe allergic reactions, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, and skin diseases. It is also used to test for an adrenal gland disorder (Cushing's syndrome). It decreases your body's natural defensive response and reduces symptoms such as swelling and allergic-type reactions. Dexamethasone (Mycogynax) is a corticosteroid hormone (glucocorticoid). This injectable form of Dexamethasone (Mycogynax) is used when a similar drug cannot be taken by mouth or when a very fast response is needed, especially in patients with severe medical conditions. Talk to your doctor about the risks and benefits of Dexamethasone (Mycogynax), especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.
This drug may also be used with other medications as a replacement for certain hormones.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This drug may also be used to prevent nausea and vomiting caused by cancer chemotherapy.
How to use Dexamethasone (Mycogynax) injection
This medication is given by injection into a vein, muscle, joint, or skin wound as directed by your doctor. Follow your doctor's directions carefully. Dosage is based on your medical condition and response to treatment. Do not increase your dose or use this drug more often than prescribed without consulting your doctor. Some patients (especially newborns) should receive the preservative-free form of this drug. In these patients, when mixing this form of the drug, be sure to use IV fluid that is also preservative-free. Use these mixtures within 24 hours.
If this medication is injected into a joint, be careful how much pressure you put on that joint, even if it is feeling better. Ask your doctor how much you can move/use the joint while it is healing.
If you have been using this medication for a long time, do not suddenly stop using it without your doctor's approval. Your dose may need to be gradually decreased to reduce symptoms such as weakness, weight loss, nausea, or extreme tiredness.
If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.
Tell your doctor if your condition persists or worsens.
Dexamethasone (Mycogynax) description
Each gram of Dexamethasone (Mycogynax) oral paste contains Dexamethasone (Mycogynax) 1 mg and sodium polyacryle 300 mg. Dexamethasone (Mycogynax) is a paste for application to the oral mucosa, containing Dexamethasone (Mycogynax) with a potent anti-inflammatory action as the active ingredient. The use of sodium polyacrylate which has a potent adhesive and coating activity on the moist surface as the base is greatly contributory to the prolonged action of Dexamethasone (Mycogynax) and the protection of wound surface: Dexamethasone (Mycogynax) is thus effective against inflammatory diseases of the oral cavity.
Dexamethasone (Mycogynax) is 9α-Fluoro-11β, 17α, 21-trihydroxy-16α-methyl-pregna-1, 4-diene-3, 20-dione. It has a molecular formula C22H29FO5 and a molecular weight of 392.47.
Dexamethasone (Mycogynax) occurs as white to light yellow crystals or a crystalline powder. It is sparingly soluble in methanol, in ethanol, in acetone or in dioxane, slightly soluble in chloroform, and practically insoluble in ether.
Dexamethasone (Mycogynax) dosage
Dexamethasone (Mycogynax) Elixir Dosage
Generic name: Dexamethasone (Mycogynax) 0.5mg in 5mL
Dosage form: elixir
- Dexamethasone (Mycogynax) tablet
Medically reviewed on October 1, 2017.
For oral administration: DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.
The initial dosage varies from 0.75 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.75 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient's response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue Dexamethasone (Mycogynax)® Elixir and transfer the patient to other therapy.
After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.
If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.
The following milligram equivalents facilitate changing to Dexamethasone (Mycogynax)® Elixir from other glucocorticoids:
|Dexamethasone (Mycogynax)||Methylprednisolone and Triamcinolone||Prednisolone and Prednisone||Hydrocortisone||Cortisone|
|0.75 mg =||4 mg =||5 mg =||20 mg =||25 mg|
Dexamethasone (Mycogynax) suppression tests
- Tests for Cushing's syndrome.
Give 1 mg of Dexamethasone (Mycogynax) orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning.
For greater accuracy, give 0.5 mg of Dexamethasone (Mycogynax) orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.
- Test to distinguish Cushing's syndrome due to pituitary ACTH excess from Cushing's syndrome due to other causes.
Give 2 mg of Dexamethasone (Mycogynax) orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Dexamethasone (Mycogynax) (Dexamethasone (Mycogynax))
- Dexamethasone (Mycogynax) Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- 14 Reviews
- Drug class: glucocorticoids
- Dexamethasone (Mycogynax) (Advanced Reading)
Other brands: Dexamethasone (Mycogynax) Intensol, Dexasone, Dexacen-4, Dexamethasone (Mycogynax),... +7 more
- Dexamethasone (Mycogynax) (FDA)
- Dexamethasone (Mycogynax) Elixir (FDA)
- Dexamethasone (Mycogynax) sodium phosphate (AHFS Monograph)
Related treatment guides
- Addison's Disease
- Adrenal Insufficiency
- Adrenocortical Insufficiency
- Adrenogenital Syndrome
- ... +54 more
Dexamethasone (Mycogynax) interactions
Tablet/Forte Tablet: Barbiturates, Phenytoin, Ephedrine, Carbamazepine, Rifampicin and Other Drugs that Stimulate Hepatic Metabolism: May lessen the effect of Dexamethasone (Mycogynax) due to enhancement of Dexamethasone (Mycogynax) metabolism. Increase in Dexamethasone (Mycogynax) dosage may be required.
CYP3A4 Inhibitors eg, Ketoconazole and Macrolide Antibiotics: May increase plasma concentrations of corticosteroids.
Indinavir, Erythromycin and Other Drugs Metabolized by CYP3A4: Dexamethasone (Mycogynax) is a moderate inducer of CYP3A4 and may increase clearance of these drugs, resulting in decreased plasma concentrations.
Oral Contraceptives and Estrogen:Can cause alterations in plasma protein-binding and metabolism of corticosteroids which can result in exposure of women to increased levels of the unbound corticosteroid for long periods of time.
Aspirin: Concomitant use of aspirin or other nonsteroidal anti-inflammatory agents (NSAIDs) and corticosteroids increases the risk of gastrointestinal adverse effects. Use aspirin cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Concomitant administration of Dexamethasone (Mycogynax) and aspirin may also cause changes in salicylate plasma protein-binding and its rate of metabolism. These changes cause lowering of plasma salicylate levels.
Warfarin: Co-administration of corticosteroids and warfarin usually results in decreased response to warfarin, although there have been conflicting results.
Monitor coagulation indices frequently to maintain the desired anticoagulant effect.
Potassium-Depleting Agents eg, Diuretics and Amphotericin-B: Observe patients closely for the development of hypokalemia. Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
Anticholinesterase Agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agents at least 24 hrs before initiating corticosteroid therapy.
Antacids: Large doses of antacids cause alteration in corticosteroid absorption.
Insulin: Concomitant administration of Dexamethasone (Mycogynax) and insulin generally requires higher doses of insulin.
Ketoconazole: Decreases the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.
Thalidomide: Toxic epidermal necrolysis has been reported when Dexamethasone (Mycogynax) was used concomitantly with thalidomide.
Indomethacin: May cause false negative results in the Dexamethasone (Mycogynax) suppression test (DST).
Other Interactions: Toxoids and Live or Inactivated Vaccines: Patients on prolonged corticosteroid therapy may exhibit diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. If possible, postpone routine administration of vaccines or toxoids until corticosteroid therapy is discontinued.
Antidiabetic Agents: Dosage adjustment of antidiabetic agents may be required because corticosteroids may increase blood glucose concentrations.
Skin Tests: Corticosteroids may suppress reactions to skin tests.
Dexamethasone (Mycogynax) side effects
Applies to Dexamethasone (Mycogynax): oral elixir, oral solution, oral tablet
Along with its needed effects, Dexamethasone (Mycogynax) (the active ingredient contained in Dexamethasone (Mycogynax)) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking Dexamethasone (Mycogynax):
- blurred vision
- decrease in the amount of urine
- fast, slow, pounding, or irregular heartbeat or pulse
- mental depression
- mood changes
- noisy, rattling breathing
- numbness or tingling in the arms or legs
- pounding in the ears
- shortness of breath
- swelling of the fingers, hands, feet, or lower legs
- trouble thinking, speaking, or walking
- troubled breathing at rest
- weight gain
- Abdominal cramping and/or burning (severe)
- abdominal pain
- bloody, black, or tarry stools
- cough or hoarseness
- darkening of skin
- decrease in height
- decreased vision
- dry mouth
- eye pain
- eye tearing
- facial hair growth in females
- fever or chills
- flushed, dry skin
- fruit-like breath odor
- full or round face, neck, or trunk
- heartburn and/or indigestion (severe and continuous)
- increased hunger
- increased thirst
- increased urination
- loss of appetite
- loss of sexual desire or ability
- lower back or side pain
- menstrual irregularities
- muscle pain or tenderness
- muscle wasting or weakness
- pain in back, ribs, arms, or legs
- painful or difficult urination
- skin rash
- trouble healing
- trouble sleeping
- unexplained weight loss
- unusual tiredness or weakness
- vision changes
- vomiting of material that looks like coffee grounds
Some side effects of Dexamethasone (Mycogynax) may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Increased appetite
- Abnormal fat deposits on the face, neck, and trunk
- dry scalp
- lightening of normal skin color
- red face
- reddish purple lines on the arms, face, legs, trunk, or groin
- swelling of the stomach area
- thinning of the scalp hair
For Healthcare Professionals
Applies to Dexamethasone (Mycogynax): compounding powder, inhalation aerosol with adapter, injectable solution, injectable suspension, intravenous solution, oral concentrate, oral liquid, oral tablet
The most commonly occurring side effects have included alteration in glucose tolerance, behavioral and mood changes, increased appetite, and weight gain; the incidence generally correlates with dosage, timing of administration, and duration of treatment.
Frequency not reported: Opportunistic infection, exacerbation of latent infections, decreased resistance to infection, immunosuppression, candidiasis, chicken pox (varicella)
Frequency not reported: Vertigo, abnormal fat deposits, malaise, sterile abscess, impaired healing, fatigue, malaise
Frequency not reported: Hiccups, pulmonary edema
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Dexamethasone (Mycogynax) (Dexamethasone (Mycogynax))." Par Pharmaceutical Inc (formerly Qualitest Pharmaceuticals Inc), Huntsville, AL.
3. "Product Information. Dexamethasone (Mycogynax) Sodium Phosphate (Dexamethasone (Mycogynax))." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
4. Sechi GP, Piras MR, Demurtas A, Tanca S, Rosati G "Dexamethasone (Mycogynax)-induced schizoaffective-like state in multiple sclerosis: prophylaxis and treatment with carbamazepine." Clin Neuropharmacol 10 (1987): 453-7
5. "Product Information. Dexamethasone (Mycogynax) (Dexamethasone (Mycogynax))." Merck & Co, Inc, West Point, PA.
6. Carroll BJ, Schroeder K, Mukhopadhyay S, Greden JF, Feinberg M, Ritchie J, Tarika J "Plasma Dexamethasone (Mycogynax) concentrations and cortisol suppression response in patients with endogenous depression." J Clin Endocrinol Metab 51 (1980): 433-7
7. Jaime Vazquez J "Persistent hiccup as a side-effect of Dexamethasone (Mycogynax) treatment." Hum Exp Toxicol 12 (1993): 52
8. Kanwar AJ, Kaur S, Dhar S, Ghosh S "Hiccup--a side-effect of pulse therapy." Dermatology 187 (1993): 279
9. Fadul CE, Lemann W, Thaler HT, Posner JB "Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease." Neurology 38 (1988): 348-52
10. McDonnell M, Evans N "Upper and lower gastrointestinal complications with Dexamethasone (Mycogynax) despite H2 antagonists." J Paediatr Child Health 31 (1995): 152-4
11. Whitmore SE "Dexamethasone (Mycogynax) injection-induced generalized dermatitis." Br J Dermatol 131 (1994): 296-7
12. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of Dexamethasone (Mycogynax) on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7
13. New MI, Peterson RE, Saenger P, Levine LS "Evidence for an unidentified ACTH-induced steroid hormone causing hypertension." J Clin Endocrinol Metab 43 (1976): 1283-93
14. Tsoi WW "Cushing's syndrome caused by analgesic/Dexamethasone (Mycogynax) preparation." Ann Pharmacother 28 (1994): 1411
15. Spenney JG, Eure CA, Kreisberg RA "Hyperglycemic, hyperosmolar, nonketoacidotic diabetes. A complication of steroid and immunosupressive therapy." Diabetes 18 (1969): 107-10
16. Francois J "Corticosteroid glaucoma." Ann Ophthalmol 9 (1977): 1075-80
17. Godel V, Regenbogen L, Stein R "On the mechanism of corticosteroid-induced ocular hypertension." Ann Ophthalmol 10 (1978): 191-6
18. Bluming AZ, Zeegen P "Cataracts induced by intermittent Dexamethasone (Mycogynax) used as an antiemetic." J Clin Oncol 4 (1986): 221-3
19. Kobayashi Y, Akaishi K, Nishio T, Kobayashi Y, Kimura Y "Posterior subcapsular cataract in nephrotic children receiving steroid therapy." Am J Dis Child 128 (1974): 671-3
20. Schmidt GB, Meier MA, Sadove MS "Sudden appearance of cardiac arrhythmias after Dexamethasone (Mycogynax)." JAMA 221 (1972): 1402-4
21. Rao G, Zikria EA, Miller WH, Samadani SR, Ford WB "Cardiac arrhythmias after Dexamethasone (Mycogynax)." JAMA 222 (1972): 1185
Some side effects of Dexamethasone (Mycogynax) may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Dexamethasone (Mycogynax) contraindications
You should not use this medication if you are allergic to Dexamethasone (Mycogynax), or if you have a fungal infection anywhere in your body.
Before taking Dexamethasone (Mycogynax), tell your doctor about all of your medical conditions, and about all other medicines you are using. There are many other diseases that can be affected by steroid use, and many other medicines that can interact with steroids.
Your steroid medication needs may change if you have any unusual stress such as a serious illness, fever or infection, or if you have surgery or a medical emergency. Tell your doctor about any such situation that affects you during treatment.
Steroid medication can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had. Tell your doctor about any illness or infection you have had within the past several weeks.
Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.
Do not receive a "live" vaccine while you are taking Dexamethasone (Mycogynax). Vaccines may not work as well while you are taking a steroid.
Do not stop using Dexamethasone (Mycogynax) suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication.
Wear a medical alert tag or carry an ID card stating that you take Dexamethasone (Mycogynax). Any medical care provider who treats you should know that you are using a steroid.
What is Metronidazole (Mycogynax)?
Metronidazole (Mycogynax) is used to treat bacterial infections in different areas of the body. The extended-release tablets are used to treat women with vaginal infections (bacterial vaginosis).
Metronidazole (Mycogynax) belongs to the class of medicines known as antibiotics. It works by killing bacteria or preventing their growth. However, Metronidazole (Mycogynax) will not work for colds, flu, or other virus infections.
Metronidazole (Mycogynax) is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Metronidazole (Mycogynax) is used in certain patients with the following medical conditions:
- Clostridium difficile diarrhea or colitis (antibiotic-associated colitis).
- Crohn's disease (inflammatory bowel disease).
- Gastritis or stomach ulcers due to Helicobacter pylori.
- Giardiasis (parasite infection in the intestines).
Metronidazole (Mycogynax) indications
Metronidazole (Mycogynax) is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of thetrichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).
Metronidazole (Mycogynax) is indicated in the treatment of asymptomatic females when the organism is associated with endocervi-citis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
Treatment of Asymptomatic Consorts.
T. vagi-nalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with Metronidazole (Mycogynax) in cases of reinfection.
Metronidazole (Mycogynax) is indicated in the treatment of acute intestinal amebiasis (amebic dysen-tery)and amebic liver abscess.
In amebic liver abscess, Metronidazole (Mycogynax) therapy does not obviate the need for aspiration or drainage of pus.
Anaerobic Bacterial Infections
Metronidazole (Mycogynax) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole (Mycogynax) therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole (Mycogynax).
In the treatment of most serious anaerobic infections, Metronidazole (Mycogynax) I.V. (Metronidazole (Mycogynax) hydrochloride) or Metronidazole (Mycogynax) I.V. RTU® (Metronidazole (Mycogynax)) is usually administered initially. This may be followed by oral ther-apy with Metronidazole (Mycogynax) (Metronidazole (Mycogynax)) at the discretion of the physician.
INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis,B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostrid-ium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species.
SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger,Peptostreptococcus species, and Fusobacte-rium species.
GYNECOLOGIC INFECTIONS, including endo-metritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcusniger, and Pepto-streptococcus species.
BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group, and Clos-tridium species.
BONE AND JOINT INFECTIONS, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group.
CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B.fragilis group.
LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.
ENDOCARDITIS caused by Bacteroides species including the B.fragilis group.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole (Mycogynax) and other antibacterial drugs, Metronidazole (Mycogynax) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Metronidazole (Mycogynax)?
Use Metronidazole (Mycogynax) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Metronidazole (Mycogynax). Talk to your pharmacist if you have questions about this information.
- If you are using Metronidazole (Mycogynax) once daily, use it at bedtime.
- Remove the cap from the tube and break the metal seal on the tube with the pointed tip of the cap. Screw the end of the applicator onto the tube. Slowly squeeze gel out of the tube and into the applicator. The plunger will stop when the applicator is full. Unscrew applicator and replace the cap on the tube.
- You may insert Metronidazole (Mycogynax) lying on your back with your knees bent or in any comfortable position. Hold the filled applicator by the barrel, and gently insert into the vagina as far as it will comfortably go. Slowly press the plunger until it stops, and then remove the applicator.
- If you will be using Metronidazole (Mycogynax) twice daily, you will need to clean the applicator after your first dose of the day and use it again for your second dose. To clean the applicator, pull the plunger out of the barrel. Wash both the plunger and barrel in warm, soapy water and rinse well. To put the applicator back together, gently push the plunger back into the barrel.
- Wash your hands immediately after using Metronidazole (Mycogynax).
- When you throw the applicator away, be sure that it is out of the reach of children and pets.
- Using Metronidazole (Mycogynax) at the same time each day will help you remember to use it.
- To clear up your infection completely, use Metronidazole (Mycogynax) for the full course of treatment. Keep using it even if you feel better in a few days.
- If you miss a dose of Metronidazole (Mycogynax), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Metronidazole (Mycogynax).
Uses of Metronidazole (Mycogynax) in details
Metronidazole (Mycogynax) is an antibiotic that is used to treat a wide variety of infections. It works by stopping the growth of certain bacteria and parasites.
This antibiotic treats only certain bacterial and parasitic infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Metronidazole (Mycogynax) may also be used with other medications to treat certain stomach/intestinal ulcers caused by a bacteria (H. pylori).
How to use Metronidazole (Mycogynax)
Take this medication by mouth as directed by your doctor. To prevent stomach upset, take this medication with food or a full glass of water or milk. The dosage is based on your medical condition and response to treatment.
Antibiotics work best when the amount of medicine in your body is kept at a constant level. Take this drug at evenly spaced intervals.
Continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.
Tell your doctor if your condition lasts or gets worse.
Metronidazole (Mycogynax) description
Each 100 mL contains Metronidazole (Mycogynax) USP 500 mg, sodium chloride USP 0.72% w/v, water for injection USP as needed.
Metronidazole (Mycogynax) injection, USP is a parenteral dosage form of the synthetic antibacterial agent 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole. The empirical formula is C6H9N3O3 and the molecular weight is 171.15.
Metronidazole (Mycogynax) injection, USP in 100 mL is a sterile, nonpyrogenic, iso-osmotic, buffered solution of 500 mg Metronidazole (Mycogynax), USP, 790 mg sodium chloride, USP, 47.6 mg dried dibasic sodium phosphate, USP and 22.9 mg anhydrous citric acid, USP. Metronidazole (Mycogynax) injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7).
Metronidazole (Mycogynax) dosage
Usual Adult Dose for Acne Rosacea
Metronidazole (Mycogynax) topical 1% gel or cream: Apply a thin film to the affected area once a day.
Metronidazole (Mycogynax) topical 0.75% gel, cream, or lotion: Apply a thin film to the affected area twice a day.
Usual Adult Dose for Bacterial Vaginosis
Insert one applicatorful of Metronidazole (Mycogynax) topical 0.75% vaginal gel intravaginally once (at bedtime) or twice a day for 5 consecutive days.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Gel, cream, lotion: Data not available
Vaginal gel: The manufacturer recommends caution when administering this drug to patients with severe hepatic disease.
The duration of topical therapy is 4 to 10 weeks depending on the nature and severity of the condition.
Patients should be advised to use Metronidazole (Mycogynax) topical less frequently or discontinue use if a reaction suggesting local irritation occurs.
Convulsive seizures and peripheral neuropathy have been reported in patients receiving oral or IV Metronidazole (Mycogynax). If abnormal neurologic signs appear, Metronidazole (Mycogynax) topical vaginal gel should be discontinued at once. The use of Metronidazole (Mycogynax) topical 1% gel should be reevaluated at once if abnormal neurologic signs appear. Metronidazole (Mycogynax) topical should be used with caution in patients with central nervous system diseases.
Metronidazole (Mycogynax) topical should be used with caution in patients with evidence of, or history of blood dyscrasia.
Although disulfiram-like reactions have not been reported in patients receiving vaginal Metronidazole (Mycogynax), the manufacturer recommends that alcohol be avoided. Metronidazole (Mycogynax) topical vaginal gel should not be used in patients who have taken disulfiram within the last 2 weeks.
Safety and efficacy have not been established in pediatric patients (less than 18 years of age).
Data not available
Metronidazole (Mycogynax) topical may cause eye irritation if applied too close to the eyes. Contact with the eyes should be avoided.
Topical areas to be treated should be washed with a mild cleanser prior to application.
The manufacturer recommends avoidance of vaginal intercourse during treatment with Metronidazole (Mycogynax) topical vaginal gel.
Metronidazole (Mycogynax) interactions
The intravaginal administration of a single 5 gram dose of Metronidazole (Mycogynax) results in relatively lower mean systemic exposure to Metronidazole (Mycogynax) that is approximately 2% to 5% of that achieved following a 500 mg oral dose of Metronidazole (Mycogynax). The following drug interactions were reported for oral Metronidazole (Mycogynax).
Use of oral Metronidazole (Mycogynax) has been associated with psychotic reactions in alcoholic patients who are using disulfiram concurrently. Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) should not be used by patients who have taken disulfiram within the last two weeks.
Use of oral Metronidazole (Mycogynax) has been associated with a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) to alcohol. Alcoholic beverages and preparations containing ethanol or propylene glycol should not be consumed during and for at least three days after Metronidazole (Mycogynax) therapy.
Coumarin and Other
Use of oral Metronidazole (Mycogynax) has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) is prescribed for patients on this type of anticoagulant therapy. In patients on oral anticoagulants, consider monitoring prothrombin time, international normalized ratio (INR), and other coagulation parameters while on Metronidazole (Mycogynax).
Short-term use of oral Metronidazole (Mycogynax) has been associated with elevation of serum lithium concentrations and, in a few cases signs of lithium toxicity, in patients stabilized on relatively high doses of lithium. Use Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) with caution in patients treated with lithium and consider monitoring lithium serum concentrations while on Metronidazole (Mycogynax).
Use of oral Metronidazole (Mycogynax) with cimetidine may prolong the half-life and decrease plasma clearance of Metronidazole (Mycogynax). No dose adjustment of Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) is necessary.
Metronidazole (Mycogynax) side effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Metronidazole (Mycogynax) compared to another formulation of vaginal Metronidazole (Mycogynax) in 220 women in a single trial. The population was non-pregnant females (age range 18 to 72 years, the mean was 33 years +/- 11 years) with bacterial vaginosis. The racial demographic of those enrolled was 71 (32%) of White, 143 (65%) of Black, 3 (1%) of Hispanic, 2 (1%) of Asian, and 1 (0%) of other. Patients administered an applicator full of Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) intravaginally once daily at bedtime for 5 days.
There were no deaths or serious adverse reactions related to drug therapy in the clinical trial. Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) was discontinued in 5 patients (2.3%) due to adverse reactions.
The incidence of all adverse reactions in Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) -treated patients was 42% (92/220). Adverse reactions occurring in ≥ 1% of patients were: fungal infection* (12%), headache (7%), pruritus (6%), abdominal pain (5%), nausea (3%), dysmenorrhea (3%), pharyngitis (2%), rash (1%), infection (1%), diarrhea (1%), breast pain (1%), and metrorrhagia (1%).
* Known or previously unrecognized vaginal candidiasis may present more prominent symptoms during therapy with Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel). Approximately 10% of patients treated with Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) developed Candida vaginitis during or immediately after therapy.
Additional uncommon events, reported by < 1% of those women treated with Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) included:
General: allergic reaction, back pain, flu syndrome, mucous membrane disorder, pain
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence, gingivitis, vomiting
Nervous System: depression, dizziness, insomnia
Respiratory System: asthma, rhinitis
Skin and Appendages: acne, sweating, urticaria
Urogenital System: breast enlargement, dysuria, female lactation, labial edema, leucorrhea, menorrhagia, pyleonephritis, salpingitis, urinary frequency, urinary tract infection, vaginitis, vulvovaginal disorder
Other Metronidazole (Mycogynax) Formulations
Other Vaginal Formulations
Other reactions that have been reported in association with the use of other formulations of Metronidazole (Mycogynax) vaginal gel include: unusual taste and decreased appetite.
Topical (Dermal) Formulations
Other reactions that have been reported in association with the use of topical (dermal) formulations of Metronidazole (Mycogynax) include skin irritation, transient skin erythema, and mild skin dryness and burning. None of these adverse reactions exceeded an incidence of 2% of patients.
The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of Metronidazole (Mycogynax):
Cardiovascular: Flattening of the T-wave may be seen in electrocardiographic tracings.
Nervous System: The most serious adverse reactions reported in patients treated with Metronidazole (Mycogynax) have been convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity. In addition, patients have reported syncope, vertigo, incoordination, ataxia, confusion, dysarthria, irritability, depression, weakness, and insomnia.
Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, “furry” tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.
Genitourinary: Overgrowth of Candida in the vagina, dyspareunia, decreased libido, proctitis.
Hematopoietic: Reversible neutropenia, reversible thrombocytopenia.
Hypersensitivity Reactions: Urticaria; erythematous rash; Stevens-Johnson Syndrome, toxic epidermal necrolysis, flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.
Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.
Metronidazole (Mycogynax) contraindications
The use of Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) is contraindicated in patients with a history of hypersensitivity to Metronidazole (Mycogynax), other nitroimidazole derivatives, or parabens. Reported reactions include urticaria; erythematous rash; Stevens-Johnson Syndrome, toxic epidermal necrolysis, flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.
Psychotic Reaction with Disulfiram
Use of oral Metronidazole (Mycogynax) is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel) to patients who have taken disulfiram within the last two weeks.
Interaction with Alcohol
Use of oral Metronidazole (Mycogynax) is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue alcohol consumption during and for at least three days after therapy with Metronidazole (Mycogynax) (Metronidazole (Mycogynax) vaginal gel).
What is Nystatin (Mycogynax)?
Nystatin (Mycogynax) belongs to the group of medicines called antifungals. The dry powder, lozenge (pastille), and liquid forms of Nystatin (Mycogynax) are used to treat fungus infections in the mouth.
Nystatin (Mycogynax) is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Nystatin (Mycogynax) is used in certain patients with the following medical condition:
- Candidiasis, oral (fungus infection of the mouth) (prevention)
Nystatin (Mycogynax) indications
Nystatin (Mycogynax) USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
Nystatin (Mycogynax) USP is not indicated for systemic, oral, intravaginal or ophthalmic use.
How should I use Nystatin (Mycogynax)?
Use Nystatin (Mycogynax) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Nystatin (Mycogynax). Talk to your pharmacist if you have questions about this information.
- Nystatin (Mycogynax) if for vaginal use only. Do not take this tablet by mouth.
- Wash your hands before and immediately after using Nystatin (Mycogynax).
- Use the applicator to insert Nystatin (Mycogynax) high into the vagina.
- Nystatin (Mycogynax) works best if it is used at the same time every day.
- To clear up your infection completely, use Nystatin (Mycogynax) for the full course of treatment. Keep using it even if you feel better in a few days.
- Continue to use Nystatin (Mycogynax) even during your period.
- If you miss a dose of Nystatin (Mycogynax), use it as soon as possible. If is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Nystatin (Mycogynax).
Uses of Nystatin (Mycogynax) in details
This medication is used to treat fungal infections of the mouth or intestines. Nystatin (Mycogynax) is an antifungal that works by stopping the growth of fungus.
Nystatin (Mycogynax) for suspension should not be used to treat fungal infections of the blood.
How to use Nystatin (Mycogynax)
Measure the prescribed amount of powder and mix it into water as directed by your doctor. Stir well and divide the mixture into a number of smaller portions as directed. Use the mixture right way. Do not prepare a supply in advance.
Place one portion of the liquid in the mouth. Swish it around the mouth and gargle if so directed. Keep the liquid in your mouth for as long as possible, then swallow or spit out as directed. Use the other portions as your doctor directs. Ask your doctor or pharmacist for more details. Avoid eating for 5-10 minutes after using this medication.
This medication is most often used four times a day or as directed by your doctor. It may take from several days to several months to complete treatment. Use this medication regularly in order to get the most benefit from it. Remember to use it at the same times each day. Dosage is based on your medical condition and response to therapy.
Continue to use this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may allow the infection to continue, resulting in a return of the infection.
Inform your doctor if your condition persists after several days of treatment or worsens at any time.
Nystatin (Mycogynax) description
Nystatin (Mycogynax) is a polyene antifungal drug to which many molds and yeasts are sensitive, including Candida spp. Nystatin (Mycogynax) has some toxicity associated with it when given intravenously, but it is not absorbed across intact skin or mucous membranes. It is considered a relatively safe drug for treating oral or gastrointestinal fungal infections.
Nystatin (Mycogynax) dosage
Usual Adult Dose for Cutaneous Candidiasis
Apply Nystatin (Mycogynax) topical cream, ointment or powder in a quantity sufficient to cover the affected area and immediately surrounding skin 2 to 4 times a day.
The powder formulation is useful for the treatment of moist areas or lesions.
Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Vaginal Candidiasis
Insert one Nystatin (Mycogynax) tablet (100,000 units) vaginally once a day, preferably at bedtime, for a total of 14 days.
Usual Pediatric Dose for Cutaneous Candidiasis
Apply Nystatin (Mycogynax) topical cream, ointment or powder in a quantity sufficient to cover the affected area and immediately surrounding skin 2 to 4 times a day.
The powder formulation is useful for the treatment of moist areas or lesions.
Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Vaginal Candidiasis
>13 <18 years: Insert one Nystatin (Mycogynax) tablet (100,000 units) vaginally once a day, preferably at bedtime, for a total of 14 days.
For fungal infections of the feet caused by Candida, dust the powder freely on the feet as well as in shoes and socks.
The vaginal tablets should be used continuously, regardless of initiation of menses.
For external use only. Avoid contact with the eyes.
Nystatin (Mycogynax) interactions
Your healthcare professionals (e.g., doctor or pharmacist) may already be aware of any possible drug interactions and may be monitoring you for it. Do not start, stop or change the dosage of any medicine before checking with them first.
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.
Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
Nystatin (Mycogynax) side effects
Applies to Nystatin (Mycogynax): oral capsule, oral suspension, oral tablet
In addition to its needed effects, some unwanted effects may be caused by Nystatin (Mycogynax) (the active ingredient contained in Nystatin (Mycogynax)). In the event that any of these side effects do occur, they may require medical attention.
Minor Side Effects
Some of the side effects that can occur with Nystatin (Mycogynax) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
- nausea or vomiting
- stomach pain
Nystatin (Mycogynax) contraindications
Do not use Nystatin (Mycogynax) topical to treat any skin condition that has not been checked by your doctor.
Nystatin (Mycogynax) topical (for the skin) is not for use to treat a vaginal yeast infection.
Avoid getting this medication in your eyes or mouth. If this does happen, rinse with water.
Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.
Call your doctor if your symptoms do not improve, or if they get worse while using Nystatin (Mycogynax) topical.
Do not share this medication with another person, even if they have the same symptoms you have.
Active ingredient matches for Mycogynax:
|Unit description / dosage (Manufacturer)||Price, USD|
|Mycogynax - 12 Vaginal Tablets||$ 12.50|
|Mycogynax 1 Blister x 12 Tablet|
List of Mycogynax substitutes (brand and generic names):
- DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Mycogynax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mycogynax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
3 consumers reported time for resultsTo what extent do I have to use Mycogynax before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 3 days and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Mycogynax. To get the time effectiveness of using Mycogynax drug by other patients, please click here.
12 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology